About Us

TriLink BioTechnologies specializes in the synthesis of highly modified nucleic acid constructs for research, diagnostic, and therapeutic applications. Since 1996, TriLink has offered cutting edge products to researchers in the fields of gene therapy, nucleoside chemotherapy, oligonucleotide therapy, next generation sequencing, vaccines, and diagnostics. The company manufactures with industry-leading technology, consistent high quality, and ready access to expert scientific support when needed. TriLink develops and manufactures oligonucleotides, mRNA transcripts, nucleotides, bioconjugation, custom chemistry, solutions for PCR & RT-PCR, and NGS library preparation kits. The oligonucleotide and mRNA solutions offered have enabled significant advancements in the biological sciences. TriLink is expanding their manufacturing potential with a new global headquarters, set to open in Fall 2019 in San Diego, CA, learn more here. A privately held company, TriLink BioTechnologies was acquired by Maravai LifeSciences in 2017. See maravai.com to learn more.

Over 20 Years as an Industry Leader in Nucleic Acid Synthesis

1996

1996

Founded in May in San Diego, California. By year-end, TriLink moves into first commercial lab space, begins shipping oligonucleotides, and hires first employees.

1997

Obtains license to synthesize radioactive compounds. TriLink quickly becomes the industry leader and one of the only companies in the world to successfully manufacture radio-labeled oligos.

1997
1998

1998

First customer-written paper citing TriLink products is published in the Journal of Immunology by David Broide et al., Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice.

1999

Expands into nucleoside triphosphates. Cofounds Solulink®, a company focused on unique bioconjugation chemistries. Outgrows first lab and expands to Nancy Ridge site. First paper under TriLink corporate name is published.

1999
2002

2002

Company continues to experience remarkable growth and expands to a 40,000 square foot building that served as the corporate headquarters.

2005

Receives first of four SBIR grants for chemically modified primers and NTPs for improved hot-start PCR, the basis of the CleanAmp® product line.

2005
2006

2006

Proven pre-clinical oligo production leads to first alliance partnership with large therapeutic oligo CMO, enabling customers to easily transition from R&D to clinical trials.

2011

Leverages expertise with complicated nucleic acids and begins IVT production of long RNA and mRNA for use in pharmaceutical research and development. First patent for CleanAmp® is granted.

2011
2014

2014

Receives ISO 9001 certification. Opens state-of-the-art GMP manufacturing facility and expands into mRNA and oligonucleotide therapeutics. Secures contract for synthesis of Ebola vaccine with Battelle. Awarded patents for proprietary CleanTag® technology.

2015

Publications citing TriLink products exceeds 6,000. Adds gram scale mRNA production and expands mRNA purification offerings. Launches CleanTag® Small RNA Library Prep kits. Cofounds ETAGEN, a company focused on gene editing technologies, with Tod Woolf.

2015
2016

2016

Strategic investment by Maravai LifeSciences.

2017

Launches CleanCap® - a patented mRNA capping method that makes remarkable improvements over existing technology.

2017
2018

2018

Receives ISO 9001:2015 certification.

2019

TriLink & Maravai move to new global headquarters. Space includes 105,000 sq. ft. facility space with 50,000 sq. ft. of custom manufacturing space, including 5 GMP suites.

2019

Company Information

Year Founded:
1996
Number of Employees:
160+
Facilities:
Headquarters, San Diego, CA USA
Key Personnel:
Brian Neel, Chief Operating Officer
Brian joined TriLink with over fifteen years of experience as a leader in the life sciences and diagnostics industries. He has significant experience in a wide array of manufacturing operations in life sciences, and worked in chemistry and molecular biology-based operations with Life Technologies (acquired by Thermo Fisher) for over 13 years. Brian has a passion for continuous improvement in operations management, and has held key site leadership roles in organic chemistry, bioproduction, and enzyme purification technologies across organizations within 3 different states, including Synthetic Genomics and GenMark. He received a B.A. in Microbiology from the University of Missouri, Columbia.

Michael Houston, Chief Scientific Officer
Mike brings over ten years of experience as a leader in the biotech and pharmaceutical industries to TriLink. Mike worked as VP of Therapeutic Development and later as CSO at PhaseRx, where he developed mRNA-based therapeutics. Mike served as Vice President of Chemistry and Formulations for Marina Biotech, where he led a team in the development of siRNA based therapies and LNP-based delivery systems. He has significant experience in peptide-based therapeutics, as demonstrated in his role as VP of Preclinical Chemistry and CMC at Ascent Therapeutics. Mike also served as Senior Director of Chemistry and Formulations at Nastech Pharmaceutics. He received a Ph.D. in bio-organic chemistry and a B.Sc. with honors in chemistry from the University of Waterloo in Ontario, Canada. 

David Weber, VP and Chief Commercial Officer
David comes to Maravai LifeSciences with over 35 years of experience in life sciences industry commercial leadership and general management. David is responsible for all marketing, sales, product development, commercial strategy, service, and support for all Maravai LifeSciences portfolio companies. Prior to joining Maravai LifeSciences, David served as Executive Vice President and Chief Commercial Officer for Affymetrix leading up to its acquisition by Thermo Fisher Scientific. Earlier in his career, David held a variety of commercial leadership roles in life science companies including Amersham Biosciences (GE Healthcare), Eksigent Technologies, Cyntellect, Stratagene, and The Linus Group. 

Harjit Kullar, VP, Marketing
Harjit comes to Maravai LifeSciences with over 15 years of experience in sales and marketing in the life sciences and diagnostics industries, most recently holding the position of Vice President of Marketing at Transgenomic. Earlier in his career, Harjit held a variety of commercial leadership roles in life science companies including Bio-Rad Laboratories, Thermo Fisher Scientific, Life Technologies, LifeSpan BioSciences, and Abcam. Harjit received a BSc in Biochemistry & Pharmacology from University of Southampton, a Ph.D. in Cancer Biology from University of Birmingham and an MBA from University of Cambridge.
Contacts for the Media:
Jennifer Dahlgren
Dahlgren Communications
(530) 263-6817
[email protected]